8 results about "Syringaresinol" patented technology

The present invention relates to a composition for preventing, ameliorating, or treating neuropathic pain, comprising syringaresinol or a pharmaceutically acceptable salt thereof as an active ingredient. The composition of the present invention may be administered to a subject for which administration of an anticancer agent is scheduled or to which an anticancer agent has been administered, or to a subject which has suffered peripheral nerve damage, to thereby prevent, ameliorate, or treat neuropathic pain.

The present application relates to the technical field of skin mucosa repair, and particularly relates to a pharmaceutical preparation for repairing skin mucosa injury. The preparation takes kaempferol, quercetin, 3-p-coumaroyl-1, 4, 6'-triacetyl sucrose, 3-p-coumaroyl-2', 3', 6'-triacetyl sucrose, (+)-syringaresinol and vitamin B12 extracted from Prunus tomentosa as active ingredients, so as to solve the problems of poor curative effect, long repair period and easy scarring of the existing skin mucosa injury repair preparation, and realize efficient, safe and high-quality skin mucosa injury repair effect.

The invention discloses a partridge extraction isolate and application thereof. According to the present invention, the chemical components of the partridge are researched, such that eight compounds are separated, and the eight compounds are respectively identified as 2-(1H-indol-3-yl) ethyl-tricosanoate (2-(1H-indol-3-yl) ethyl-tricosate) (1), lariciresinol (2), pinoresin (3), syringesin (4), dioscin (5), coniferyl aldehyde (6), syringaldehyde (7) and sinapinalde (8); the compounds are separated from partridge for the first time, the compound (1) is a new compound, the immunomodulatory effect of the compound (1) on mouse splenic lymphocytes is measured, and the result shows that the compound (1) can remarkably induce secretion of TNF-alpha and IL-6, and shows that the compound has immune activation potential equivalent to that of a classical TLR agonist.

The application relates to the technical field of plant invasion prevention, and discloses application of aikenol monomethyl ether in inhibition of growth of Mikania micrantha. The aikenol monomethyl ether is dissolved in dimethyl sulfoxide, and then a 1200 microgram / mL mother liquor is prepared by using purified water; 1.333 mL of the mother liquor with a concentration of 1200 microgram / mL is taken in a clean container, and purified water is added to make up to 40 mL, so that 40 mL of aikenol monomethyl ether solution with a concentration of 40 microgram / mL is obtained; the aikenol monomethyl ether solution is sprayed on Mikania micrantha plants with 4-6 leaves; purified water is sprayed as a control; and on the fifth day, the difference in plant height between the treatment group and the control group is obviously observed. Therefore, the aikenol monomethyl ether can be used for preparing a medicine for inhibiting the growth of Mikania micrantha, so that the growth of Mikania micrantha is inhibited.

The invention relates to a method for determining the content of effective components in a Kunxinning preparation. Comprising the following steps: step 1, preparing a reference substance solution, namely respectively taking a proper amount of one or two or more of catalpol, rehmannia glutinosa liboside D, paeoniflorin, calycosin-7-glucoside, (-)-syringinol-4-O-beta-D-furanselinosyl-(1-2)-beta-D-glucopyranoside, curculigoside, icariin and baohuoside I reference substances; preparing a reference substance solution; step 2, preparation of a test solution: taking a Kunxinning preparation, weighing the Kunxinning preparation, placing the Kunxinning preparation in a measuring flask, adding methanol to dilute the Kunxinning preparation to a scale, filtering the Kunxinning preparation, and taking a subsequent filtrate; step 3, a determination method: respectively and precisely sucking the reference substance solution and the test solution, injecting the solutions into a high performance liquid chromatograph, and determining component types and / or component contents; the chromatographic conditions are as follows: octadecylsilane chemically bonded silica is used as a filler, water is used as a mobile phase A, acetonitrile is used as a mobile phase B, gradient elution is performed, the flow velocity is 0.5-1.5 mL / min, the column temperature is 25-35 DEG C, the detection wavelength is 200-300 nm, and the sample size is 10-30 [mu] L.

The invention relates to the technical field of skin mucosa repair, in particular to a pharmaceutical preparation for repairing skin mucosa injury. According to the preparation, kaempferol, quercetin, 3-p-coumaroyl-1, 4, 6 '-triacetyl cane sugar, 3-p-coumaroyl-2', 3 ', 6'-triacetyl cane sugar, (+)-clove resinol and vitamin B12 which are extracted from Nanking cherries are used as active ingredients, the problems that an existing skin mucous membrane injury repairing preparation is poor in curative effect, long in repairing period, prone to scar remaining and the like are solved, and the efficient, safe and high-quality skin mucous membrane injury repairing effect can be achieved.

The application discloses a method for screening and determining active ingredients of Wuji drink, and a method for determining the content of active ingredients of Wuji drink, which comprises the following steps: adding methanol as an extraction solvent to a Wuji drink dry extract, performing ultrasonic extraction, filtering, and obtaining a test product solution; preparing 3-O-p-coumaroyl quinic acid control product solution, DL-syringaresinol control product solution and methyl ophiopogonanone B control product solution by using methanol; precisely sucking the control product solution and the test product solution respectively; determining the peak area by using UPLC-MS / MS method; and calculating the content of the three components. The application firstly establishes a method for determining the content of three active components, i.e., 3-O-p-coumaroyl quinic acid, DL-syringaresinol and methyl ophiopogonanone B, in a classic medicinal diet Wuji drink dry extract, wherein the 3-O-p-coumaroyl quinic acid is an effective component for determining the content of Wuji drink, and the content determination method meets the relevant regulations for health food declaration.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating chronic obstructive pulmonary disease as well as a pharmaceutical preparation and application thereof. The pharmaceutical composition comprises syringaresinol and cryptomeria diol, the cryptomeria diol can promote absorption of the syringaresinol so as to enhance the effect of the syringaresinol on treating the chronic obstructive pulmonary disease, the syringaresinol and the cryptomeria diol act synergistically, and the weight ratio of the syringaresinol to the cryptomeria diol is (8: 1)-(1: 1). The pharmaceutical composition derived from natural products is provided for treatment of the chronic obstructive pulmonary disease, and the pharmaceutical composition has a good treatment effect on the chronic obstructive pulmonary disease and has no obvious adverse reaction or toxic and side effects.